OraSure (OSUR) Wins FDA Approval for OraQuick(R) In-Home HIV Test

Article Stock Quotes (1) Comments (0)

OraSure Technologies, Inc. (Nasdaq: OSUR) today announced that the U.S. FDA has approved the Company's OraQuick® In-Home HIV Test for sale directly to consumers in the over-the-counter (OTC) market – making it the first and only rapid OTC HIV test approved in the U.S. The OraQuick® In-Home HIV Test can detect antibodies to both HIV-1 and HIV-2 with an oral swab, providing a confidential in-home testing option with results in as little as 20 minutes. It is the first rapid diagnostic test for any infectious disease that has been approved by the FDA for sale over the counter.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Peregrine Pharma (PPHM), FDA Reach Agreement Over Bavituximab Phase III Design
• Royalty Pharma Raises Elan (ELN) Bid to $12.50/share
• Mylan (MYL) Launches Generic Tricor Tabs (ABBV)

Create E-mail Alert Related Categories

Corporate News, FDA, Trading Halts

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?